Arabic Arabic English English French French German German
dark

Gyroscope Therapeutics Files Registration Statement for Proposed Initial Public Offering in the United States

Gyroscope Therapeutics, a clinical-stage gene therapy company focused on treating diseases of the eye, today announced it has filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering (“IPO”) in the United States of its American Depositary Shares (“ADSs”), each representing one ordinary share. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Synertech Medical Launches Single-Use Sterile Dural Repair Kit in the US to Improve Operating Room Efficiency

Next Post

St. Luke’s Provides Treatment for COVID ‘Long Haulers’

Related Posts
Total
0
Share